Top 50 Life Science Startup Investors (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
SOSV
VC Fund
|
51 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
ARCH Venture Partners
VC Fund
|
29 | United States, China, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $7.8M–$230M |
|
Sofinnova Partners
VC Fund
|
28 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6M–$102M |
|
Alexandria Venture Investments
VC Fund
|
25 | United States, Canada, France | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2M–$150M |
|
Northpond Ventures
VC Fund
|
21 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Life Science | $10M–$100M |
|
Google Ventures
VC Fund
|
20 | United States, United Kingdom, Israel | Series A, Series B, Seed | Software, Health Care, Biotechnology | $1M–$106M |
|
OrbiMed
VC Fund
|
19 | United States, China, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $10M–$149M |
|
Novartis Venture Fund
VC Fund
|
18 | United States, Switzerland, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $5.1M–$105M |
|
Parkwalk Advisors
VC Fund
|
18 | United Kingdom, United States, Philippines | Seed, Series A, Series B | Biotechnology, Health Care, Software | $982k–$46M |
|
RA Capital Management
VC Fund
|
17 | United States, United Kingdom, Canada | Series B, Series C, Post-IPO Equity | Biotechnology, Health Care, Therapeutics | $26M–$235M |
|
Bpifrance
VC Fund
|
17 | France, United States, Switzerland | Seed, Series A | Software, Information Technology, Health Care | $713k–$34M |
|
Atlas Venture
VC Fund
|
16 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.2M–$115M |
|
Oxford Science Enterprises
VC Fund
|
15 | United Kingdom, United States, Finland | Seed, Series A, Series B | Health Care, Biotechnology, Software | $1.3M–$168M |
|
DCVC
VC Fund
|
15 | United States, Canada, United Kingdom | Seed, Series A, Series B | Software, Artificial Intelligence, Machine Learning | $1.5M–$130M |
|
8VC
VC Fund
|
15 | United States, United Kingdom, Canada | Series A, Seed, Series B | Software, Health Care, Artificial Intelligence | $2.7M–$175M |
|
UK Innovation & Science Seed Fund
VC Fund
|
15 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Medical | $393k–$14M |
|
M Ventures
VC Fund
|
15 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Third Rock Ventures
VC Fund
|
15 | United States | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $11M–$150M |
|
Fifty Years
VC Fund
|
15 | United States, Germany, Canada | Seed, Series A, Series B | Biotechnology, Health Care, Artificial Intelligence | $2M–$91M |
|
Omega Funds
VC Fund
|
13 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $14M–$208M |
|
Versant Ventures
VC Fund
|
13 | United States, Switzerland, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.7M–$108M |
|
Civilization Ventures
VC Fund
|
13 | United States, United Kingdom, Brazil | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $1.7M–$144M |
|
Lux Capital
VC Fund
|
13 | United States, United Kingdom, Canada | Series A, Seed, Series B | Software, Artificial Intelligence, Health Care | $1.8M–$150M |
|
Alix Ventures
VC Fund
|
13 | United States | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Life Science | $2M–$70M |
|
Novo Holdings
VC Fund
|
13 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $8M–$130M |
|
SR One
VC Fund
|
13 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.7M–$140M |
|
Kurma Partners
VC Fund
|
12 | France, Switzerland, Spain | Series A, Seed, Series B | Health Care, Biotechnology, Medical | $2.3M–$80M |
|
Andreessen Horowitz
VC Fund
|
12 | United States, United Kingdom, Brazil | Series A, Seed, Series B | Software, Information Technology, Artificial Intelligence | $1.5M–$107M |
|
Prox Ventures
VC Fund
|
12 | China, United States, United Kingdom | Seed, Series A | Medical, Biotechnology, Health Care | $1.9M–$28M |
|
Jonathan Milner
Angel
|
11 | United Kingdom, United States, Spain | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $537k–$56M |
|
Horizons Ventures
VC Fund
|
11 | United States, United Kingdom, Canada | Series A, Series B, Seed | Biotechnology, Software, Artificial Intelligence | $1M–$110M |
|
Catalio Capital Management
VC Fund
|
11 | United States, Switzerland, Israel | Series A, Series B | Biotechnology, Health Care, Life Science | $18M–$150M |
|
Cormorant Asset Management
VC Fund
|
11 | United States, China, Switzerland | Series B, Series C, Series A | Biotechnology, Health Care, Medical | $16M–$200M |
|
Khosla Ventures
VC Fund
|
11 | United States, India, United Kingdom | Series A, Series B, Seed | Software, Artificial Intelligence, Health Care | $2M–$100M |
|
MPM Capital
VC Fund
|
11 | United States, Canada, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Pharmaceutical | $9M–$116M |
|
Hatteras Venture Partners
VC Fund
|
11 | United States, Canada | Series A, Series B, Series C | Health Care, Biotechnology, Medical | $5M–$90M |
|
Takeda Ventures
VC Fund
|
11 | United States, United Kingdom, Israel | Series A, Series B | Biotechnology, Health Care, Therapeutics | $10M–$130M |
|
Artis Ventures
VC Fund
|
11 | United States, United Kingdom, India | Series A, Series B, Seed | Health Care, Biotechnology, Software | $2M–$127M |
|
KdT Ventures
VC Fund
|
11 | United States, India, Canada | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $2.6M–$175M |
|
Casdin Capital
VC Fund
|
11 | United States, China, France | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $10M–$200M |
|
Forbion Capital Partners
VC Fund
|
11 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $12M–$176M |
|
Dementia Discovery Fund
VC Fund
|
10 | United States, United Kingdom, Israel | Seed, Series A | Biotechnology, Health Care, Therapeutics | $5.9M–$77M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
10 | Germany, Switzerland, United States | Seed, Series A | Software, Biotechnology, Information Technology | $909k–$33M |
|
Seventure Partners
VC Fund
|
10 | France, United States, Germany | Series A, Series B | Biotechnology, Software, Health Care | $3.1M–$65M |
|
Sahsen Ventures
VC Fund
|
10 | United States, China, Ghana | Seed, Series A | Biotechnology, Health Care, Non Profit | $1.2M–$81M |
|
General Catalyst
VC Fund
|
10 | United States, United Kingdom, India | Series A, Seed, Series B | Software, Artificial Intelligence, Health Care | $1.5M–$140M |
|
Flagship Pioneering
VC Fund
|
10 | United States, Canada, United Kingdom | Series B, Series C, Series A | Biotechnology, Health Care, Medical | $5.5M–$140M |
|
Alumni Ventures
VC Fund
|
10 | United States, United Kingdom, Canada | Seed, Series A, Series B | Software, Artificial Intelligence, Information Technology | $1.4M–$86M |
|
Longwood Fund
VC Fund
|
10 | United States, United Kingdom, Italy | Series A, Series B, Series C | Biotechnology, Therapeutics, Health Care | $16M–$152M |
|
Development Bank of Wales
VC Fund
|
10 | United Kingdom, Australia, United States | Seed, Debt Financing | Software, Health Care, Biotechnology | $18k–$3.7M |
| Access all 5402 investors in Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, China, United Kingdom
Investor stats
- Total investments: 381
- Round size: Series A $7.8M–$212M; Series B $13M–$230M; Series C $15M–$175M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
- Bitterroot Bio — Bitterroot Bio is pioneering the emerging field of cardio-immunology, which investigates the interplay between the immune system and cardiovascular health.
- TFC Therapeutics — TFC Therapeutics is a biotechnology company developing novel biologics to target and eliminate key drivers of cancer.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 298
- Round size: Series A $6M–$65M; Series B $10M–$102M; Series C $12M–$100M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- protera — Protera is advancing the science of protein engineering to address some of the most critical problems and opportunities in food, agriculture, the environment and human health. We streamline protein design and development with MADI, our proprietary deep learning algorithm, to predict high value protein products and enzymes with unprecedented speed.Our in-house lab generates small quantities of the new predicted structures to validate their desired performance. Upon lab validation, we collaborate with our clients on next steps to move from pilot to industrial scale production.
- Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
- T-Therapeutics — T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. .
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Canada, France
Investor stats
- Total investments: 244
- Round size: Seed $2M–$31M; Series A $12M–$100M; Series B $22M–$150M
- Lead/follow: 7% lead, 93% follow
Portfolio highlights
- miRecule — MiRecule is an early-stage biotechnology company that focuses on developing microRNA-based therapeutics. It features a genomic-based drug development platform that integrates genomic sequencing, expression, and prognostic data from cancer patients. The company was founded in 2016 and headquartered in Gaithersburg, United States.
- Marvin Health — Marvin is a mental health service for physicians. We're ending the one-size-fits-all approach to teletherapy, helping you to set a teletherapy action plan.
- Affinia Therapeutics — Affinia Therapeutics is expanding what's possible in adeno-associated virus (AAV) gene therapy today and bringing transformative medicines for people.
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 131
- Round size: Series A $12M–$68M; Series B $10M–$100M; Series C $22M–$85M
- Lead/follow: 61% lead, 39% follow
Portfolio highlights
- VieCure — The VieCure platform is an Clinical Decision Support solution in Oncology that combines the power of artificial intelligence, codified clinical rules and pathways, precision oncology, telehealth, smartphone technology, and the EMR to transform cancer care.
- Culture Biosciences — Culture Biosciences develops automated bio-reactor that helps biotech companies optimize their manufacturing processes and brings products to market faster. The company also builds automated tools for fermentation. It has a digital bio-manufacturing platform to enable scientists to run, monitor, and analyze bio-reactors faster than traditionalapproaches by robotic sample handling and cloud data monitoring and analysis.Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California.
- Sound Agriculture — Discover Sound Agriculture, an innovative agriculture company harnessing nature-based solutions that enhance resilience and sustainability.
GV supports innovative founders moving the world forward.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 1011
- Round size: Seed $1M–$13M; Series A $5.4M–$86M; Series B $15M–$106M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $100M in 2014
Portfolio highlights
- Smarterer — Individuals and Fortune 500 companies use Smarterer to help close the gap between the skills they have and the skills they need. Their dynamic assessment engine leverages the freshest crowdsourced tests around, to rapidly pinpoint skill level with a credible score. In November 2014, Pluralsight, the global leader in online learning for serioussoftware developers, IT specialists and creative technologists, acquired Smarterer. As the world's largest curated e-learning library for professionals, the company offers instant access to more than 3,500 courses authored by top experts. Smarterer will continue to power crowdsourced assessments for freelancer marketplaces, e-learning providers and enterprise companies anywhere people need to prove their skills to connect with professional opportunities. The Smarterer community has answered over 56 million during 1.7 million test sessions, across hundreds of tests.
- Nearby — KANTINSLOT adalah sebuah situs slot gacor terpercaya dengan peluang kena scatter yang sangat mudah. Nikmati sensasi bermain kantin slot online dengan link login resmi yang cepat dan aman. Saatnya raih jackpot besar setiap hari!
- Cord Project — Cord is incredibly simple, incredibly fast voice messaging that lets you chat with one friend or shout to a whole group of friends. Start chatting for free on iPhone or Android now.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 581
- Round size: Series A $10M–$116M; Series B $24M–$149M; Series C $15M–$131M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Galecto — Damora Therapeutics is working to fundamentally redefine care for people with blood disorders by bringing forward optimized therapies that dramatically improve patient outcomes.
- Insilico Medicine — Artificial Intelligence for Drug Discovery and Aging Research
- Star Therapeutics — Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 210
- Round size: Series A $5.1M–$81M; Series B $11M–$105M; Series C $9M–$75M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $200M in 2009
Portfolio highlights
- Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
- Bionano Genomics — Discover how Bionano is striving to elevate health and wellness for all through optical genome mapping (OGM) solutions that transform the way the world sees the genome.
- Mediar Therapeutics — Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Philippines
Investor stats
- Total investments: 258
- Round size: Seed $982k–$4.7M; Series A $1.6M–$13M; Series B $2M–$46M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
- Bramble Energy — Bramble Energy is an innovator energy technology company that designs and manufactures high-performance, low-cost, and fuel cell stack. The company ability to leverage the global high-volume PCB industry means that they are the first fuel cell company with the manufacturing capacity to supply gigawatts of fuel cell hardware, something the batteryindustry has spent many years and £B’s to achieve.Bramble Energy specifically uses a printed circuit board (PCB) technology to form the structural parts of the fuel cell. It also provides products including modular PCBFC stacks, H20:20W PCBFC system, custom design PCBFC, and 500W PCBFC stack.Bramble Energy was founded in 2016 and is based in London, England, United Kingdom.
- Echion Technologies — Echion Technologies is a spinout from the University of Cambridge Engineering Department, using proprietary battery active materials to develop next-generation Li-ion batteries.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series C, Post-IPO Equity
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 428
- Round size: Series B $26M–$152M; Series C $40M–$200M; Post-IPO Equity $30M–$235M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Star Therapeutics — Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
- Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A
- Geography: France, United States, Switzerland
Investor stats
- Total investments: 1039
- Round size: Seed $713k–$6.9M; Series A $2.6M–$34M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Hiqute Diamond — High quality diamond plates for high-end applications
- Pitchy — Create professional videos without technical expertise. Our online video editor helps you easily make business videos.
- Siteflow — For many years digital transformation of the manufacturing industry has been underway. However, for regulated industries and operations that combine complex reporting workflows, project manufacturing and mobility for the field, few digital solutions meet the expectations. As a result, on those sites, tools and work methods haven’t changed so muchthe past decades while quality and safety requirements have exploded.That is around those challenges that professionnals from the nuclear industry, special works and software experts have gathered, to create Siteflow, the first cloud-based field service management software designed for complex operations (Nuclear, Oil&Gas…).A solution designed for end-userBeyond technical specificities from those markets, we have leveraged learnings from industries that have already been through digital transformation: every time user acceptance is key to make those challenging projects a success.This is why at Siteflow, our obsession is to design the most simple interfaces, and functionalities that bring value directly for our users, in order to simplify their daily tasks, to ease collaboration with their colleagues and to help them focus on what really matters.A change management program to facilitate digital transformationAs we all know, the choice of a software solution is just part of the puzzle to implement a digital transformation program. Organizations need to be re-designed as day-to-day activities of engineers, project managers and operators are directly concerned. Based upon our experience, we help our customers for a smooth transition to operational excellence.
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 416
- Round size: Series A $3.2M–$75M; Series B $8M–$115M; Series C $6M–$95M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Grockit — Grockit is a pioneering online social learning company. Grockit has proven that people learn more, faster through combining social learning mechanics and multi-media learning content to help people teach and learn from others. Grockit.com offers Test Prep services for GMAT, IIM CAT, LSAT, GRE, ACT, SAT and AP Calculus and AP History tests.Grockit has built a social learning test prep platform for license and direct-to-consumer products. Florida Virtual Schools, KIPP Schools, Georgetown University and other schools have deployed Grockit services.
- IFM Therapeutics — IFM Therapeutics is a provider of small molecule that module novel targets in the innate immune system. The company and its academic collaborators combine unparalleled expertise in innate immunity with seasoned drug discovery and development professionals. Its subsidiary IFM Due is focused on the discovery and developing antagonists of thecGAS/STING pathway for the treatment of inflammation, neuroinflammation, autoimmunity and cancer. IFM Discovery, a newly financed incubator entity within the IFM enterprise, is prosecuting a basket of genetically-validated targets as next-generation therapies for inflammation, neuroinflammation, autoimmunity and fibrosis
- Lifordi Immunotherapeutics — Lifordi is among the first companies to leverage the success of antibody-drug conjugates (ADC) to develop treatments for autoimmune and inflammatory disorders.
Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Finland
Investor stats
- Total investments: 163
- Round size: Seed $1.3M–$10M; Series A $5M–$46M; Series B $8.5M–$168M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $327M in 2022
Portfolio highlights
- Prolific — Launch your study to tens of thousands of trusted participants in minutes. Recruit niche or representative samples on-demand. Prolific builds the most powerful and flexible tools for online research. Sign up for free.
- Archangel Lightworks — Archangel Lightworks is integrating space and air assets using laser communication.
- Quantum Motion — Quantum Motion delivers scalable silicon-based quantum computing using standard semiconductor manufacturing technology.
We are deep tech venture capital.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Machine Learning
- Stage:Seed, Series A, Series B
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 382
- Round size: Seed $1.5M–$10M; Series A $5.7M–$50M; Series B $15M–$130M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely still investing — raised $1B in 2023
Portfolio highlights
- Noetik — Noetik is an AI-native biotechnology company. Our mission is to leverage advanced machine learning methods to discover and develop cancer immunotherapies.
- Petra — Petra is a robotics company that can bury utilities in the most difficult and disaster-prone areas on earth.
- Slip Robotics — Auto-load and auto-unload any truck in 5 minutes with SlipBots to drive 10X speed, safety, and savings across the supply chain. With Slip, truckers don't wait and forklift drivers don't risk it.
8VC is a technology and life sciences investment firm that partners with founders to develop transformational technologies. The firm focuses on creating long-term economic and societal value through its investments across various sectors, including healthcare and logistics.
Show more...Investment focus
- Industry: Software, Health Care, Artificial Intelligence
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 471
- Round size: Seed $2.7M–$13M; Series A $7.4M–$55M; Series B $16M–$175M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- DataHub — DataHub Core is the #1 open source platform with a uniquely scalable and extensible metadata graph supporting manual and automated data management. DataHub Cloud is an enterprise-ready SaaS solution providing a fully-managed service of DataHub Core with additional AI-powered capabilities in discovery, observability, and governance to accelerateproduction-readiness of AI and data assets.
- Middleware — Middleware's observability platform gives you complete visibility into your tech stack to monitor and diagnose issues at scale with total control over your data.
- Flywheel.io — Flywheel is a data management and analysis platform built specifically for scientists and the researcher's workflow. They empower research momentum by focusing on data and medical image capture, content management, scientific computation, and collaboration. With reproducible research in mind, they combine open-source methods from topuniversities, a modern web user interface, and an extensible compute engine based on containerization technology. The result is a software platform to accelerate discovery and help researchers do science, not IT.Flywheel accelerates new scientific discoveries in life-science, biotech, and academic imaging research through cloud-scale collaboration. As a result, imaging researchers are able to avoid innovation bottlenecks, and accelerate discovery by doing more science, and less IT.
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 131
- Round size: Seed $393k–$5.9M; Series A $2.9M–$14M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- HonuWorx — HonuWorx is a subsea robotics company founded with a mission to replace surface vessels with underwater deployment platforms.
- NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
- Aquark Technologies — Aquark Technologies develops atom systems to develop quantum applications, including atomic clocks, sensors, and navigation systems. Aquark develops a technique to miniaturize cold atom systems using unique laser geometry that is based on more than 10 years of proprietary research at the University of Southampton.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 165
- Round size: Seed $2.4M–$21M; Series A $5.6M–$46M; Series B $15M–$100M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
- Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
- Prexton Therapeutics — Voici la page d'accueil du site web
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States
Investor stats
- Total investments: 145
- Round size: Series A $17M–$102M; Series B $11M–$150M; Series C $14M–$146M
- Lead/follow: 44% lead, 56% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- CytomX Therapeutics — CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.
- Agios Pharmaceuticals — Over the 12+ years Agios has been in existence, we have remained committed to patients first and to following the science. Our legacy is rooted in a powerful set of strengths, values and competencies. We have built on our core differentiators to make a positive difference for patients through truly differentiated therapies. This foundation will remain constant at Agios and accelerate our impact moving forward.
- Synnovation Therapeutics — Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers. It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer. Leveraging its deep expertise in medicinal chemistry, cancer biology, andpatient-focused precision medicine, it builds a diverse pipeline of novel small-molecule targeted therapies. It aims to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.
WE BACK HEROES using technology to solve the world's biggest problems
Show more...Investment focus
- Industry: Biotechnology, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Series B
- Geography: United States, Germany, Canada
Investor stats
- Total investments: 162
- Round size: Seed $2M–$15M; Series A $8.5M–$40M; Series B $16M–$91M
- Lead/follow: 18% lead, 82% follow
- Last fund: Likely still investing — raised $90M in 2021
Portfolio highlights
- Farcast — Unlocking satellite internet capacity through user terminal innovation
- Solugen — Solugen's mission is to decarbonize the chemicals industry. Solugen combines synthetic biology with metal catalysis to make carbon negative chemicals at scale.Solugen's patented approach takes advantage of bio-inspired reactions to use plant material as a low-cost feedstock to produce novel products cost-competitive with thecompetition.
- Valence Discovery — Empowering drug discovery scientists with the latest advances in AI-enabled drug design
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 146
- Round size: Series A $16M–$187M; Series B $35M–$162M; Series C $14M–$208M
- Lead/follow: 25% lead, 75% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Ousia Pharma — Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates
- Third Arc Bio — Third Arc Bio is advancing antibody technology by unlocking the powerful biology of immune synapses to address solid tumors and autoimmune diseases.
- Anjarium Biosciences — Pioneering the next generation of non-viral gene therapy - by tackling more diseases, more precisely and in a more personalized way.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, Canada
Investor stats
- Total investments: 280
- Round size: Series A $4.7M–$80M; Series B $10M–$105M; Series C $12M–$108M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Passage Bio — Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families.
- Nested Therapeutics — Nested Therapeutics is a Cambridge-based VC-backed stealth biotech company. The company's focus is on finding and creating new precision oncology small-molecule drugs targeted toward cancer genes. Nested Therapeutics was established in 2021 in Cambridge, Massachusetts.
- Dualitas Therapeutics — Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders and other conditions. With a growing collection of innovative cell surface proximity engagers and our in-house DualScreen™ discovery engine, our pipeline
DIGITAL HEALTH / AI DIGITAL HEALTH / AI GENE / CELL THERAPIES NASDAQ: RCKT GENE / CELL THERAPIES NASDAQ: RCKT GENOMICS / DIAGNOSTICS GENOMICS / DIAGNOSTICS SYNTHETIC
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Brazil
Investor stats
- Total investments: 73
- Round size: Seed $1.7M–$16M; Series A $8.1M–$30M; Series B $26M–$144M
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- OxCan — Enabling curative cancer treatment through early detection
- Wyndly — Retrain your allergies through sublingual (under-the-tongue) treatment plans. Virtual appointments. Treatment delivered. Get started after your first consult with a board-certified doctor for $49.99.
- Foresight Diagnostics — We develop innovative diagnostics to advance decision-making in oncology drug development and patient care.
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 512
- Round size: Seed $1.8M–$22M; Series A $7M–$70M; Series B $13M–$150M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $100M in 2007
Portfolio highlights
- Clarifai — Clarifai is the leading Machine Learning, Computer Vision, NLP Platform. Label, train, deploy models on one AI platform for developers & data scientists.
- Shapeways — Shapeways is the #1 online 3D printing service company. Working with over a million customers since 2007 - Get 3D products and parts delivered to over 100 countries.
- Primer — Primer makes powerful mission-ready AI software designed to work in your environment, on your data. We help national security teams sift through massive unstructured data sets to find the needle in the haystack, understand and visualize their data, and act collaboratively. Our mission is to empower decisions that can be defended, and acted upon confidently.
Supporting early stage Life Science startups driving patient impact. Born from our collective experience as founders, we set out to build the fund we wanted to raise from....
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Seed, Series A, Pre-Seed
- Geography: United States
Investor stats
- Total investments: 22
- Round size: Seed $2M–$12M; Pre-Seed $2.7M–$2.7M; Series A $12M–$70M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- Elegen — Skip cloning with the only entirely cell-free DNA synthesis provider. Sequences up to 7 kb. Error rates as low as 1:70,000/bp. Manufactured in USA, NGS-verified and shipped globally in as few business days.
- iOrganBio — iOrganBio is a pioneering cell production platform that uses CellForge to facilitate the intelligent manufacturing of human cells and organoids.
- Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 331
- Round size: Series A $8M–$118M; Series B $12M–$130M; Series C $30M–$115M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- AlloCure — AlloCure is a biotechnology company, develops cell therapies for the treatment of various kidney diseases, organ transplants, and multi-organ injuries. It offers biological therapeutics for acute kidney injuries. AlloCure is based in Burlington, Massachusetts. It has operations in Salt Lake City, Utah, and Hamburg, Germany.The company isdedicated to the development of off-the-shelf biological therapies to treat serious and debilitating diseases that afflict millions of people around the world. AlloCure's unique technology uses processed cells derived from human bone marrow to treat a wide variety of diseases. AlloCure was founded on the unique and proprietary technology developed by Dr. Christof Westenfelder and Dr. Axel Zander. Westenfelder and Zander are world-renowned scientists who have dedicated their careers to developing effective therapies for kidney disease. AlloCure has operations in Salt Lake City Utah and Hamburg Germany.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
- Cleveland Diagnostics — Cleveland Diagnostics is developing a breakthrough technology to discover new class of diagnostics tests with high sensitivity and specificity for many cancers - early on, when cancer is still curable.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 185
- Round size: Series A $3.7M–$140M; Series B $15M–$114M; Series C $22M–$115M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Turning Point Therapeutics — The Investor Relations website contains information about Turning Point Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
- Decibel Therapeutics — Decibel Therapeutics is a developer of hearing disorder therapeutics intended to protect, repair and restore hearing. The company's therapeutics have provided insights into the link between hearing dysfunction and inner ear pathology and it has capabilities to encompass animal models, drug delivery to the inner ear, imaging, inner earPK/PD modeling and measurement, bioinformatics, genetics and target identification, enabling patients to experience hearing loss therapies with different forms of hearing disorders for their recovery.
- MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Seed, Series B
- Geography: France, Switzerland, Spain
Investor stats
- Total investments: 129
- Round size: Seed $2.3M–$13M; Series A $3.8M–$74M; Series B $8.8M–$80M
- Lead/follow: 50% lead, 50% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Nuevocor — Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts.
- Medlumics — Medlumics is a medical device start-up born in 2009 from a compromise with improving human living standards by means of technology.
- Vico Therapeutics — Pioneering RNA-based science to target the root cause of rare genetic neurological diseases VO659: The first clinical candidate directly targeting the CAG repea
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, Brazil
Investor stats
- Total investments: 1608
- Round size: Seed $1.5M–$15M; Series A $9M–$52M; Series B $16M–$107M
- Lead/follow: 48% lead, 52% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Slack — Slack is a global collaboration hub that makes people’s working lives simpler, more pleasant, and more productive. From global Fortune 100 companies to corner markets, businesses, and teams of every kind use Slack to bring the right people together with all the right information. Slack is headquartered in San Francisco California and has nineoffices around the world.
- Wiz — Organizations of all sizes and industries use Wiz to rapidly identify and remove the most critical risks in AWS, Azure, GCP, and Kubernetes so they can build faster and more securely.
- Setpoint.io — Originators, Asset Managers and Lenders use Setpoint's technology and capital to power asset-backed transactions.
Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: China, United States, United Kingdom
Investor stats
- Total investments: 73
- Round size: Seed $1.9M–$5.6M; Series A $2.8M–$28M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- DotBio — DotBio is a biopharmaceutical company specialized in next-generation domain antibody therapies.
- Brise Pharma — Brise Pharma operates in the scientific research and technical service industry.
- Coastar Therapeutics — Coastar Therapeutics develops an erythrocyte enveloped virus delivery technology platform to perform repeated virus dosing. It evades recognition and attack by the immune system to address the challenges of systemic and repeated administration of drug therapies. Coastar's process technology and “red blood cell membranes only” enable thecompany to overcome the challenges of mass production and standardization, and has cost advantages. The company's first product targets oncolytic viruses and is developing ELCV solutions for other therapies.The company was founded in 2017 and is based in San Diego, CAlifornia.
Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 61
- Round size: Seed $537k–$16M; Series A $4.1M–$50M; Series B $1.6M–$56M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Nuclera — Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis. Nuclera has since grown to fifty-seven employees across two continents as the Company delivers on its founders’ vision to make biology accessible to everyone through desktop bioprinting. With desktop bioprinting, researchers and scientists will be empowered totake control of biology through streamlined access to a next-day supply of proteins and genes.
- 52 North Health — At 52 North we are developing fully-integrated clinical, AI and medical-device based systems.
- Constructive Bio — We place non-canonical amino acids at precise positions in proteins and peptides to create therapeutics with new properties, then manufacture them through fermentation.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investing in the deep science and technology that can propel humanity towards a radically better future.
Show more...Investment focus
- Industry: Biotechnology, Software, Artificial Intelligence
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 250
- Round size: Seed $1M–$11M; Series A $6.2M–$50M; Series B $8M–$110M
- Lead/follow: 44% lead, 56% follow
Portfolio highlights
- Scopely — Scopely is a global interactive entertainment and mobile-first games company, home to many top-grossing, award-winning franchises including “Star Trek™ Fleet Command,” “MARVEL Strike Force,” “Scrabble® GO,” “WWE Champions” and “Yahtzee® With Buddies,” among others. Scopely creates, publishes and live-operates immersive games that empower adirected-by-consumer™ experience. Founded in 2011, Scopely is fueled by a world-class team and a proprietary technology platform Playgami that supports one of the most diversified portfolios in the mobile games industry. Recognized multiple times as one of Fast Company’s “World’s Most Innovative Companies,” Scopely is a multi-billion-dollar business due to its ability to create long-lasting game experiences that players enjoy for years. Scopely has global operations across 17 markets (Asia-Pacific - Bangalore, Seoul, Shanghai, Singapore, Tokyo; EMEA - Barcelona, Dublin, Helsinki, Kyiv, London, Seville, Tel Aviv; North America - Boston, Boulder, Culver City, Mountain View, San Francisco), with additional game studio partners across four continents. For more information, visit www.scopely.com.
- Synthace — The Synthace Experiment Platform lets you design powerful experiments, run them in your lab, & gather automatically structured datasets. No code necessary.
- Amper Music — Amper is an AI music composition company that develops tools for content creators of all kinds. Learn about our new enterprise platform, Score, as well as our creator API.
Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by Catalio Capital Management, an elite group of world-renowned, serial scientist-entrepreneurs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series A, Series B
- Geography: United States, Switzerland, Israel
Investor stats
- Total investments: 115
- Round size: Series A $18M–$120M; Series B $26M–$150M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Avava — Avava is a Pioneer precision skin therapy to improve the quality of life for patients around the world.
- Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
- Medical Informatics — Medical Informatics offers solutions that give care teams access to the data they need to take action for alarm management and safety. The company’s Sickbay software platform enables continuous data collection from a comprehensive set of devices. Ultimately their alarm management solutions reduce alarm noise at the patient level, and send the rightalarms to care providers.Medical Informatics Corp was founded by Emma Fauss and Craig Rusin in 2010 and is based in Houston, Texas.
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, China, Switzerland
Investor stats
- Total investments: 185
- Round size: Series A $16M–$102M; Series B $35M–$150M; Series C $33M–$200M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $393M in 2019
Portfolio highlights
- Axonis Therapeutics — AXONIS Therapeutics, Inc. is advancing breakthrough discoveries to develop first-in-class therapies for neurological disorders.
- Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
- Rapport Therapeutics — Precision medicines to match the complexity of the human brain.
Khosla Ventures is a venture capital firm that invests in early- to late-stage companies across sectors like AI, healthcare, sustainability, and consumer technology. It manages multiple funds, focusing on startups with innovative technologies or business models. The firm primarily targets sectors like AI, climate tech, digital health, and medtech,offering strategic support to help build long-lasting companies.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Series B, Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1075
- Round size: Seed $2M–$16M; Series A $5.5M–$44M; Series B $10M–$100M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $557M in 2022
Portfolio highlights
- Loop — Loop Health is bringing ease and choice to patients seeking major medical treatments. We've brought together family physicians, top specialists, and leading hospitals in Pune – to provide options, transparency, and ease to patients and their families. Loop Coordinators help patients match with a doctor, compare treatment costs, get secondopinions, and complete admission formalities – removing the stress and making lives easier for the patient and their families.
- Siolta Therapeutics — Siolta Therapeutics is harnessing science from the human microbiome to design next-generation microbial therapeutics. Learn more.
- Rejuvenation Technologies — Rejuvenation Technologies is a biotechnology company that developed nucleoside-modified TERT mRNA to safely and rapidly extend telomeres. The company is headquartered in Mountain View, California.
Powering Breakthroughs in Life Sciences
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Series B, Series C
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 224
- Round size: Series A $9M–$84M; Series B $20M–$116M; Series C $12M–$100M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $850M in 2021
Portfolio highlights
- Orna Therapeutics — Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.
- Syndax Pharmaceuticals — Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor,in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.
- Werewolf Therapeutics — Developing transformative conditionally activated proinflammatory immune modulating medicines to unleash a powerful attack on cancer.
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Canada
Investor stats
- Total investments: 129
- Round size: Series A $5.2M–$41M; Series B $5M–$90M; Series C $8M–$88M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Ribometrix — The Next Frontier of Drug Discovery
- Contego Medical — Better Outcomes. Simplified. Neurovascular Peripheral Vascular Neurovascular
- G1 Therapeutics — G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigationaltherapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer.
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 104
- Round size: Series A $10M–$58M; Series B $20M–$130M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Integra Therapeutics — Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.
- Accipiter Biosciences — Accipiter Biosciences is a biotechnology company.
- Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.
Artis Ventures has spent over a decade backing bold teams who take the hard path, building market-defining companies to re-shape, re-invent, and re-make industries.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, India
Investor stats
- Total investments: 140
- Round size: Seed $2M–$40M; Series A $4M–$55M; Series B $20M–$127M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- LookSharp — The industry leader for qualified and diverse candidates to get discovered and hired. Search for job and internship opportunities, access career advice, and connect directly with top employers.
- Practice Fusion — 'Deliver better care more efficiently with the #1 electronic health record. Our industry-leading EHR was developed with feedback from over 150,000 professionals.'
- Second Front Systems — The continuous accreditation and deployment of commercial software is crucial for U.S. national security missions. With Second Front Systems' Game Warden platform, you'll be achieving exactly that.
KdT Ventures is the standard for early-stage frontier science investing.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United States, India, Canada
Investor stats
- Total investments: 88
- Round size: Seed $2.6M–$13M; Series A $8.5M–$70M; Series B $25M–$175M
- Lead/follow: 9% lead, 91% follow
- Last fund: Likely still investing — raised $80M in 2022
Portfolio highlights
- Elegen — Skip cloning with the only entirely cell-free DNA synthesis provider. Sequences up to 7 kb. Error rates as low as 1:70,000/bp. Manufactured in USA, NGS-verified and shipped globally in as few business days.
- Checkerspot — A biology-driven platform creating specialized lipids from fermentation
- Tierra Biosciences — Speed, scale and simplicity with protein synthesis on-demand. Discover your portal to thousands of custom proteins. Get testable material with a single input.
Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, China, France
Investor stats
- Total investments: 190
- Round size: Series A $10M–$200M; Series B $32M–$150M; Series C $36M–$200M
- Lead/follow: 17% lead, 83% follow
- Last fund: May invest from a new fund soon — raised $30M in 2018
Portfolio highlights
- Adlai Nortye — Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment.
- Beacon Biosignals — AI + EEG to change the way patients are treated for disorders of the brain.
- Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 178
- Round size: Series A $14M–$176M; Series B $15M–$155M; Series C $12M–$113M
- Lead/follow: 51% lead, 49% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
- NOVAMEAT — NOVAMEAT produces plant-based meat substitutes through advanced food printing and tissue engineering technologies. Join the #novameat movement.
- Oxyrane UK — Oxyrane UK Limited is a biopharmaceutical company dedicated to the development of novel and biosuperior enzyme replacement therapies (ERT) to treat lysosomal storage diseases, a class of more than 40 rare, inherited diseases. Founded in 2006, the Company is headquartered in Manchester, United Kingdom with research facilities in Ghent, Belgium.
SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Seed, Series A
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 50
- Round size: Seed $5.9M–$20M; Series A $7M–$77M
- Lead/follow: 42% lead, 58% follow
- Last fund: May invest from a new fund soon — raised $337M in 2018
Portfolio highlights
- Violet Therapeutics — Violet Therapeutics is a healthcare company that operates in stealth mode.
- Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
- Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 542
- Round size: Seed $909k–$6.5M; Series A $3M–$33M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $522M in 2022
Portfolio highlights
- Sdui — Sdui is the solution for mobile communication in schools. With amazingly easy features for messaging, timetables and a wide range of third party integrations, the app digitizes processes and reduces administrative effort. Within two years, Sdui has reached hundreds of institutions and grown a serious reputation in the educational market.
- envelio — We are driving forward the energy transition with our smart grid solutions for grid operators. Get information now and plan smart!
- VisioLab — Instantly scan products for self-checkout, using the iPad camera - no barcodes needed. Designed for speed, simplicity and human centricity.
Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Series A, Series B
- Geography: France, United States, Germany
Investor stats
- Total investments: 215
- Round size: Series A $3.1M–$24M; Series B $3.3M–$65M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Otoqi — Otoqi is a vehicle delivery platform that develops connected services and logistics solutions for the automotive professionals.
- Flexvelop — Flexvelop combines financial technology with circular economy to add innovative values to the core function of equipment funding.Local vendors and online-shops integrate Flexvelop as a seamless embedded payment option. Business customers are now able to #flex new equipment per click right at the point of sale. Insurance is already covered, andour customers have now the weekly option, to buy- or return their equipment, easily. This enables a new world of worry-free and flexible business growth.We #flex business equipment from €300 up to €20.000 per item; e.g. coffee-machines, laptops, gym- or dental-equipment,... anything you need for your business.NEXT GENERATION PAYMENTS + Technological Innovation: fully automatic embedded payment option + Economical Innovation: optionality (rent/buy/return) + insurance included + Ecological Innovation: sustainability (contributing to a circular economy) = Enabling worry-free flexible business developmentForget renting. Forget leasing. Grow smart - flex it!
- wealthpilot — We believe in wealth management democratization. We believe that everyone should be able to control their financial life and reach their financial goals. We do that by combining simple-to-use technology with professional personal advice for all financial assets. Our Software-as-a-Service Platform automatically analyzes and plans all types of assetsand enables professional advisors to deliver a data-driven and truly personal wealth management.
Sahsen Ventures is a venture capital firm making investments in for-profit and nonprofit organizations with an emphasis on technology and biotechnology. It was established in 2016 and is based in Seattle, Washington.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Non Profit
- Stage:Seed, Series A
- Geography: United States, China, Ghana
Investor stats
- Total investments: 85
- Round size: Seed $1.2M–$25M; Series A $13M–$81M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
- Synthesize Bio — Deep biomedical data is the key to unlocking discoveries and creating therapies. Synthesize Bio uses AI to reduce data collection and analysis from months to minutes for a fraction of the cost in time, personnel, and materials.
- Archon Biosciences — Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management.
Investing in powerful, positive change that endures
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, India
Investor stats
- Total investments: 1516
- Round size: Seed $1.5M–$18M; Series A $5.5M–$65M; Series B $12M–$140M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Goodstack — Goodstack is a SaaS and fintech platform for managing charitable donations.
- Endo Health — Reverse Your Diabetes With a Game
- Windsurf — Windsurf offers an AI coding assistant designed to enhance developers' productivity. The platform features an integrated development environment that simplifies coding tasks and streamlines workflows. It supports multiple operating systems, including Mac, Windows, and Linux, making it accessible to a wide range of users. Windsurf provides afree version for individual developers, while teams can access additional features through an enterprise offering. This flexibility allows users to choose the option that best suits their needs. By focusing on usability and functionality, Windsurf aims to improve its users' overall coding experience.
We create breakthroughs in human health and sustainability and build bioplatform companies . Companies founded
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 198
- Round size: Series A $5.5M–$75M; Series B $11M–$140M; Series C $12M–$123M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Montai Therapeutics — Harnessing untapped diverse chemistry with AI-enabled drug discovery to develop breakthrough small molecule medicines for chronic disease.
- Terrana Biosciences — Terrana's innovative technological platform enables resilient agriculture in a fast changing world by providing RNA-based plant health solutions.
- Quotient Therapeutics — Discover how Quotient is pioneering a new field of genetics with somatic genomics to unveil a universe of genetic information and develop new therapies.
Access curated startup investment opportunities and diversified venture capital exposure designed for accredited investors.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 1413
- Round size: Seed $1.4M–$10M; Series A $5.2M–$37M; Series B $12M–$86M
- Lead/follow: 14% lead, 86% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Polygraf — AI Usage Behavioral Control Layer - Polygraf sits directly between enterprise users, agents, and AI systems to inspect every AI interaction before data leaves your security boundary.
- Operant — Own OperantAi.com today. Secure checkout and guided transfer support. No hidden fees.
- Arda Therapeutics — Arda Therapeutics is a biotechnology company taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions. Their approach starts by using single-cell data to identify pathogenic cells and specific markers to target them. They then design therapies to eliminate these - and only these - cells.Arda wasfounded in 2021 in the San Francisco Bay Area, CA.
Longwood creates and invests in science-based companies that develop novel solutions for important medical problems
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Health Care
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Italy
Investor stats
- Total investments: 72
- Round size: Series A $16M–$100M; Series B $25M–$152M; Series C $17M–$100M
- Lead/follow: 15% lead, 85% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- ImmuneID — SANTOTO4D adalah situs togel WLA resmi terpercaya dengan pasaran lengkap sistem keamanan tinggi dan layanan cepat Daftar sekarang dan raih jackpot besar
- Newleos Therapeutics — Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.
- Vertero — Axial Therapeutics is a biotechnology company fundamentally changing the treatment of neurological diseases and disorders by harnessing groundbreaking science in the microbiome-gut-brain axis.
Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Debt Financing
- Geography: United Kingdom, Australia, United States
Investor stats
- Total investments: 214
- Round size: Seed $327k–$3.7M; Debt Financing $18k–$3.7M
- Lead/follow: 59% lead, 41% follow
- Last fund: May invest from a new fund soon — raised $25M in 2018
Portfolio highlights
- Tourhub — tourhub - We collect tours from hundreds of suppliers around the world and provide an easy way for you to search and find those that are of interest.
- Bond Digital Health — Bond Digital Health is a technology company developing end-to-end digital connectivity for the point-of-care diagnostics market. Developed by founders Ian Bond and Dave Taylor and originally designed as a patient self-management tool, Bond’s digital technology was remodeled to meet the needs of a client - a world-renowned innovator in point-of-carediagnostics and the lateral flow industry. The client required a digital platform consisting of a patient-facing mobile app and cloud data management for their new quantitative diagnostic test for chronic lung disease. They shared their experiences of working with us with a collaborator company who quickly commissioned Bond to develop a similar product for chronic wound care. Others in the lateral flow industry recognised that an affordable, compliant and scalable solution was available highlighting a huge unmet need in an expanding market. Bond is working in strategic partnerships with key industry leaders to create the next generation of digitally connected lateral flow diagnostics that provide an elevated user experience and enhanced real-time decision-making through the power of data aggregation and data analytics.Our regulatory strategy ensures that the solutions we create are secure, reliable and compliant with regulatory standards, making us a trusted partner to leaders in human health, animal health and agri-food globally.In Bond Digital Health we believe that collaborative working is the only way to tackle some of the major health challenges the world is nowadays facing. Our technology brings the life sciences industry closer together to create solutions that improve the lives of millions.Let’s make a difference together!
- CoinCover — Cryptocurrency insurance-backed technology to make cryptocurrency safe for individuals and businesses to hold and use.
Life Science Investor funding at a glance
Stats across 4.9k deals from 5.4k investors.
Access all 5402 investors in Life Science startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science Investors investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 5402 investors investing in Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!